Actively Recruiting
Pilot Study of Neck Traction Device to Reduce Gabapentin or Pregabalin Use for Neuropathic Itch of Scalp, Arms, and Upper Back
Led by Mayo Clinic · Updated on 2026-09-09
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether cervical traction, a device-based therapy, can reduce the use of GABAergic medications such as gabapentin or pregabalin in people experiencing neuropathic itch affecting the scalp, arms, and upper back without primary skin rash. This pilot study explores treatment options to address neuropathic pruritus and aims to provide alternative approaches to medication management. Participants will use a home cervical traction device daily for 12 weeks while continuing their stable doses of gabapentin or pregabalin. They will complete electronic itch severity surveys every two weeks during this period. Based on these results, the study team may adjust their medication dose by up to 33%. The study focuses on a single group receiving this intervention without a placebo or comparator. During the study, participants will be monitored through regular electronic surveys assessing itch severity at multiple time points. The primary measurement is the change in GABAergic medication use from baseline to 12 weeks. Secondary outcomes include itch severity scores recorded at baseline and every two weeks up to 72 days. Participants are expected to comply with study visits, questionnaires, and medication adjustments under medical supervision throughout the 12-week treatment period.
CONDITIONS
Brief Title
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here